<DOC>
	<DOC>NCT00310544</DOC>
	<brief_summary>The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.</brief_summary>
	<brief_title>Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction</brief_title>
	<detailed_description>This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>At least 8 weeks postdocumented myocardial infarction (heart attack) History of radiation therapy to the chest Clinically unstable Any contraindication for MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>